Medicine
Erythromycin 333 mg delayed-release tablet
Erythromycin 333 mg delayed-release tablet is a generic prescription medicine for oral use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted between 15°C and 30°C…
Key facts
- Active ingredient (INN)
- Erythromycin
- Brand
- Sold under the generic name
- Strength
- 333 mg
- Dosage form
- Delayed-release tablet
- Route
- Oral
- Packs
- 100 tablets, 500 tablets, 30 tablets and 4 more
- Manufacturers
- Torrent PharmaceuticalsIndiaAmneal Pharmaceuticals NYWilshire Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F)
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D10AF02 Erythromycin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 July 2019
- Identifiers
- RxCUI 310155, 310157, 315090DailyMed set ID 66b0d891-8756-43d1-b046-6dba787dd96f, e9b5abbb-2952-44ce-8cbb-415d9be23df4, bb641ed4-8093-4e15-9cb9-8921b1093d50NDC 13668-587, 52536-183, 69238-1472Application ANDA211975, ANDA062298, ANDA210954
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, delayed release in 1 bottle | 13668-587-01 | Torrent PharmaceuticalsIndia | 21 October 2024 |
| 500 tablet, delayed release in 1 bottle | 13668-587-05 | Torrent PharmaceuticalsIndia | 21 October 2024 |
| 30 tablet, delayed release in 1 bottle | 13668-587-30 | Torrent PharmaceuticalsIndia | 21 October 2024 |
| 100 tablet, delayed release in 1 bottle | 69238-1472-1 | Amneal Pharmaceuticals NY | 7 July 2019 |
| 30 tablet, delayed release in 1 bottle | 69238-1472-3 | Amneal Pharmaceuticals NY | 27 August 2021 |
| 30 tablet, delayed release in 1 bottle | 52536-183-03 | Wilshire Pharmaceuticals | 22 July 2019 |
| 100 tablet, delayed release in 1 bottle | 52536-183-10 | Wilshire Pharmaceuticals | 22 July 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 June 1964 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Erythromycin 333 mg delayed-release tablet.
Other strengths and forms of Erythromycin
Clinical summary
Erythromycin is a macrolide antimicrobial indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, among other approved uses. MedsAcross supplies Erythromycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ErythromycinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ery-Ped prescribing information (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)) · U.S. National Library of Medicine, DailyMed
Need Erythromycin 333 mg delayed-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.